
Third Harmonic Bio Announces Strategic Review, Reduces Workforce by 50 Amidst Intensifying Biotech Competition
Third Harmonic Bio’s THB335 Shows Promise in Phase 1 Trial On Tuesday, Third Harmonic Bio, Inc. (THRD) unveiled the results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of THB335, a novel small molecule inhibitor of…